Principal Investigator: Dylan Zylla, MD
Study sponsor: Mayo Clinic
Locations:
-HealthPartners Frauenshuh Cancer Center
-HealthPartners Cancer Center at Regions Hospital
Phase of Study: Phase 1
Purpose of study: This early phase I trial studies the side effects of ketoconazole and how well it works in treating participants with ongoing EGFR inhibitor-induced rash. Ketoconazole may reduce the symptoms related to EGFR inhibitor therapy and improve EGFR inhibitor-induced rash.
Inclusion Criteria:
-Patient has developed a rash or symptoms of a rash (cutaneous burning) characteristic of an EGFR inhibitor (health-care provider report of the rash with no other documentation is permitted).
-Patient is anticipated to continue for at least 28 days with an EGFR inhibitor or restart? 14 days of registration and continue for at least 28 days.
-Patient is willing to provide a skin biopsy for correlative research; Note: Can be waived with permission of study chair (documentation such as an email must be provided).
-Patient must complete baseline quality of life (QOL) packet.
Exclusion Criteria:
-Patient has a prior allergy or intolerance of ketoconazole.
-Patient has an allergy or intolerance to sulfites.
Study Contact:
Alissa Gavenda
(952) 992-5705
Alissa.Gavenda@ParkNicollet.com